Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Presented to President.

Message on Senate action sent to the House.

Passed Senate without amendment by Voice Vote. (consideration: CR S5120)

Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)

Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.

Motion to reconsider laid on the table Agreed to without objection.

On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

Considered as unfinished business. (consideration: CR H5159)

At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.

DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.

Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)

Mr. Guthrie moved to suspend the rules and pass the bill, as amended.

Placed on the Union Calendar, Calendar No. 637.

Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.

Committee Consideration and Mark-up Session Held

Forwarded by Subcommittee to Full Committee by Voice Vote.

Subcommittee Consideration and Mark-up Session Held

Referred to the Subcommittee on Health.

Referred to the House Committee on Energy and Commerce.

Introduced in House